A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults
NCT05142306
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
23
Enrollment
INDUSTRY
Sponsor class
Conditions
SARS-CoV-2 Infection
Interventions
BIOLOGICAL:
COVID-HIG
Sponsor
Emergent BioSolutions
Collaborators
[object Object]